Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-06-0339PMID 17041089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of ABCG2/BCRP in biology and medicine.

  2006cited by this paper
• The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

  2005influential reference
• 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.

  2005cited by this paper
• Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver

  2005cited by this paper
• Modulatory effects of plant phenols on human multidrug‐resistance proteins 1, 4 and 5 (ABCC1, 4 and 5)

  2005cited by this paper
• FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

  2005cited by this paper
• A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• Mutations

  2004cited by this paper
• Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol

  2004cited by this paper
• The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme*

  2004cited by this paper
• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  2003cited by this paper
• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  2002cited by this paper
• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  2002cited by this paper
• Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

  2002cited by this paper
• C 421 A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q 141 K Protein and Low-Level Drug Resistance 1

  2002cited by this paper
• Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays

  2002cited by this paper
• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  2002cited by this paper
• Phenomenology and Scientific Progress

  2002cited by this paper
• Role Reversal for Anticancer Agents

  2002cited by this paper
• Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).

  2002cited by this paper
• The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

  2002cited by this paper
• Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

  2001cited by this paper
• Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

  2001cited by this paper
• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  2001cited by this paper
• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

  2001cited by this paper
• Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.

  2000cited by this paper
• The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).

  2000cited by this paper
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  2000cited by this paper
• Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

  1999cited by this paper
• Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

  1999cited by this paper
• The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

  1999cited by this paper
• Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

  1999cited by this paper
• Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

  1999cited by this paper
• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  1999cited by this paper
• A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

  1998cited by this paper
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

  1998cited by this paper
• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

  1996cited by this paper
• Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.

  1992cited by this paper
• Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.

  1990cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Annual Review of Pharmacology

  1975cited by this paper

• A Holistic Review of Oncological Drug Targets and Trajectories of Resistance in Cancer Therapy

  2026cites this paper
• Advanced cancer therapy: unlocking the potential of small molecule inhibitors.

  2025cites this paper
• Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer

  2021cites this paper
• Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.

  2021cites this paper
• Polymeric nano-carriers for on-demand delivery of genes via specific responses to stimuli.

  2020cites this paper
• Identification and characterization of drug resistance mechanisms in cancer cells against Aurora kinase inhibitors CYC116 and ZM447439

  2020cites this paper
• Potential physical and biological barriers leading to failure of cancer chemotherapy

  2019cites this paper
• How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

  2018cites this paper
• The cyclin-dependent kinase inhibitor, JNJ-7706621, improves in vitro developmental competence of porcine parthenogenetic activation and somatic cell nuclear transfer embryos.

  2018cites this paper
• First examples of diprotonated guanazolinium salts with fluoro-anions

  2017cites this paper
• [Role of breast cancer resistance protein in drug disposition].

  2016cites this paper
• Multi-kinase inhibitors, AURKs and cancer

  2016cites this paper
• Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers.

  2015cites this paper
• Characterization of a Pyrazolo[4,3‐d]pyrimidine Inhibitor of Cyclin‐Dependent Kinases 2 and 5 and Aurora A With Pro‐Apoptotic and Anti‐Angiogenic Activity In Vitro

  2015influential citation
• Enhanced chemotherapy efficacy by co-delivery of shABCG2 and doxorubicin with a pH-responsive charge-reversible layered graphene oxide nanocomplex.

  2015cites this paper
• Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.

  2014cites this paper
• Identification et mécanisme d'action de modulateurs sélectifs du transporteur ABCG2 responsable de la chimiorésistance de cellules cancéreuses

  2014cites this paper
• Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents

  2014cites this paper
• Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

  2014cites this paper
• Induction of apoptosis in anoikis-resistant breast cancer stem cells by supercritical CO2 extracts from Citrus hassaku Hort ex Tanaka

  2014cites this paper
• A novel approach to the design of selective inhibitors for cell cycle cyclin dependent kinases

  2013cites this paper
• Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)

  2013cites this paper
• Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications

  2013cites this paper
• Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

  2013cites this paper
• Predicting substrates of the human breast cancer resistance protein using a support vector machine method

  2013cites this paper
• New structure–activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity

  2013cites this paper
• Computational analysis and predictive modeling of polymorph descriptors

  2013cites this paper
• ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.

  2013cites this paper
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012cites this paper
• Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

  2012cites this paper
• Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability

  2012cites this paper
• Towards the development of fluorescent probes targeting aldehyde dehydrogenase (ALDH) in cancer. Expression and epigenetic modulation of ALDH1A1, ALDH2 and ALDH3A1 in selected in vitro models.

  2012cites this paper
• Topics on Drug Metabolism

  2012cites this paper
• A new series of 3,5-diamino-1,2,4-triazolium(1+) inorganic salts and their potential in crystal engineering of novel NLO materials

  2012cites this paper
• Aurora kinase inhibitors: Progress towards the clinic

  2012cites this paper
• Chinese a Nti鄄 Cancer a Ssociation

  2012cites this paper
• Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging

  2011cites this paper
• Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization activities and transport functions

  2011cites this paper
• Synthesis, crystal structure, IR-spectral data and some properties of 3,5-diamino-1,2,4-triazolium tetrafluoroborate and hexafluorosilicate

  2011cites this paper
• A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method

  2011cites this paper
• In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).

  2011cites this paper
• The challenge of exploiting ABCG2 in the clinic.

  2011cites this paper
• Cyclin-dependent kinase inhibitors as anticancer drugs.

  2010cites this paper
• Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

  2010cites this paper
• Targeting intestinal transporters for optimizing oral drug absorption.

  2010cites this paper
• Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation

  2010cites this paper
• ABCG2 Transports and Transfers Heme to Albumin through Its Large Extracellular Loop*

  2010cites this paper
• Suppression of ABCG2 inhibits cancer cell proliferation

  2009cites this paper
• ABCG2: a perspective.

  2009cites this paper
• Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

  2009cites this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cites this paper
• Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

  2009cites this paper
• Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

  2009cites this paper
• ABCG2: structure, function and role in drug response.

  2008cites this paper
• Aurora-B kinase inhibitors for cancer chemotherapy.

  2008cites this paper
• Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

  2008cites this paper
• ABCG2: structure, function and role in drug response

  2008cites this paper
• Progress in the evaluation of CDK inhibitors as anti-tumor agents.

  2008cites this paper
• Update on aurora kinase inhibitors in gynecologic malignancies.

  2008cites this paper
• Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure

  2007cites this paper
• Aurora kinase targeted therapeutics in oncology: past, present and future

  2007cites this paper
• High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.

  2007cites this paper
• Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

  2007cites this paper